Samara Regional Clinical Oncology Dispensary

Abstract. The fi rst real-life experience with cabazitaxel for the treatment of metastatic castration-resistant prostate cancer has been described. Cabazitaxel was used as second-line treatment following disease progression on docetaxel treatment. Cabazitaxel was administered to two patients, with stable disease being registered in both the patients. Toxicity was mild, maximum grade 2, neutropenia and asthenia were registered. In general, Cabazitaxel had a manageable safety profi le.

Key words: castration-resistant prostate cancer, chemotherapy, Docetaxel, Cabazitaxel.